Who owns BIOCRYST PHARMACEUTICALS INC?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of BCRX from SEC Form 13F filings across 334 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 334 institutions disclosed 243.8M shares of BIOCRYST PHARMACEUTICALS INC worth $2.03B — about 95.4% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
334
13F holders
$2.03B
value, 2026 filers
95.4%
of shares outstanding (243.8M sh)
54
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of BCRX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 24.3M | $202.7M | 0.0% | 9.5% | +1.8% |
| 2 | DEERFIELD MANAGEMENT COMPANY, L.P. | 15.5M | $129.0M | 2.0% | 6.1% | +2.6% |
| 3 | STATE STREET CORP | 12.3M | $102.4M | 0.0% | 4.8% | -19.1% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 11.3M | $93.9M | 0.0% | 4.4% | -0.9% |
| 5 | TCG Crossover Management, LLC | 11.0M | $91.8M | 2.6% | 4.3% | 0.0% |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 10.5M | $87.7M | 0.0% | 4.1% | -5.4% |
| 7 | PERCEPTIVE ADVISORS LLC | 10.3M | $85.8M | 1.5% | 4% | -0.1% |
| 8 | Janus Henderson Group Ltd.NEW | 10.3M | $85.3M | 0.0% | 4% | new |
| 9 | TWO SIGMA INVESTMENTS, LP | 7.2M | $60.0M | 0.0% | 2.8% | +6.3% |
| 10 | Jones Hill Capital LPNEW | 7.1M | $59.0M | 10.0% | 2.8% | new |
| 11 | Aberdeen Group plc | 6.5M | $53.9M | 0.1% | 2.5% | +21.8% |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 6.1M | $50.4M | 0.0% | 2.4% | -3.2% |
| 13 | BANK OF AMERICA CORP /DE/ | 5.4M | $45.2M | 0.0% | 2.1% | +13.1% |
| 14 | UBS Group AG | 5.4M | $44.9M | 0.0% | 2.1% | +6.0% |
| 15 | GOLDMAN SACHS GROUP INC | 4.2M | $35.3M | 0.0% | 1.7% | -5.5% |
| 16 | Nuveen, LLC | 4.0M | $33.7M | 0.0% | 1.6% | +0.9% |
| 17 | Frazier Life Sciences Management, L.P. | 4.0M | $33.4M | 0.8% | 1.6% | 0.0% |
| 18 | JUPITER ASSET MANAGEMENT LTD | 4.0M | $33.3M | 0.2% | 1.6% | +143.2% |
| 19 | MORGAN STANLEY | 3.5M | $28.7M | 0.0% | 1.3% | +72.5% |
| 20 | GW&K Investment Management, LLC | 3.4M | $28.0M | 0.2% | 1.3% | +6.0% |
| 21 | HRT FINANCIAL LP | 2.7M | $22.5M | 0.0% | 1.1% | +149.6% |
| 22 | Kynam Capital Management, LP | 2.5M | $21.0M | 1.2% | 1% | 0.0% |
| 23 | Candriam S.C.A. | 2.5M | $21.0M | 0.1% | 1% | 0.0% |
| 24 | Fisher Asset Management, LLC | 2.4M | $20.4M | 0.0% | 1% | -6.0% |
| 25 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2.3M | $19.1M | 0.0% | 0.9% | -2.4% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.